{"id":70941,"date":"2023-05-24T13:03:45","date_gmt":"2023-05-24T11:03:45","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?post_type=resources&p=70941"},"modified":"2026-01-27T14:41:47","modified_gmt":"2026-01-27T13:41:47","slug":"minaris-regenerative-medicine-streamlining-contract-manufacturing-with-veeva-vault-quality-suite-applications","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/minaris-regenerative-medicine-streamlining-contract-manufacturing-with-veeva-vault-quality-suite-applications\/","title":{"rendered":"Minaris Regenerative Medicine Streamlining Contract Manufacturing with ³Ô¹Ï±¬ÁÏ Vault Quality Suite Applications"},"content":{"rendered":"

Global CDMO unifies quality content and training for greater visibility and agility<\/em><\/p>\n

BARCELONA, Spain \u2014 24 May 2023<\/strong> \u2014 ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced that Minaris Regenerative Medicine, a leading contract development and manufacturing organization (CDMO) focused on cell and gene therapies, selected ³Ô¹Ï±¬ÁÏ QualityDocs<\/a> and ³Ô¹Ï±¬ÁÏ Training<\/a> to advance its global quality operations. Minaris Regenerative Medicine will use ³Ô¹Ï±¬ÁÏ\u2019s unified quality applications to better collaborate with customers and partners, improve transparency across functions, and ensure compliance. <\/p>\n

\u201cAs a pioneer in cell and gene therapy, we needed a scalable quality management foundation to drive efficiency and compliance,\u201d said Prakash Manwani, chief digital officer, Minaris Regenerative Medicine. \u201cWith ³Ô¹Ï±¬ÁÏ Vault Quality Suite applications, we are well-positioned for GxP document control and continuous quality improvement. ³Ô¹Ï±¬ÁÏ as a platform is a critical piece of our global IT roadmap and vision to create a digitally connected ecosystem for our operations, customers, and patients alike.\u201d<\/p>\n

Minaris Regenerative Medicine\u2019s vision is \u201ccreating future cell therapy miracles together,\u201d and the ³Ô¹Ï±¬ÁÏ platform will advance its ability to do so, to the benefit of both its clients and those patients suffering from a wide range of diseases for which cell and gene therapy holds promise. The CDMO will use ³Ô¹Ï±¬ÁÏ Quality Cloud<\/a> applications to modernize its operations globally, including Vault QualityDocs to control access and distribution of content and Vault Training to create and manage role-based learning programs. By adopting connected applications on a single platform, Minaris Regenerative Medicine will streamline its global quality processes. <\/p>\n

\u201c³Ô¹Ï±¬ÁÏ gives us easy access to documentation and training for more agility on site,\u201d said Adela Balducci, executive director, head of quality, North America, Minaris Regenerative Medicine. \u201cBeing on the same platform as many of our customers will deliver efficiencies in information sharing and reporting, improving how we work with clients for a competitive edge.\u201d <\/p>\n

\u201cMinaris Regenerative Medicine is developing and manufacturing potentially life-changing cell therapies to treat cancers and genetic disorders that do not have any known cures,\u201d said Ashley McMillan, senior director, ³Ô¹Ï±¬ÁÏ Vault Quality strategy. \u201c³Ô¹Ï±¬ÁÏ Vault Quality applications will be key in supporting quality for these important therapies. We\u2019re excited to be a strategic partner helping them transform content and employee qualification management.\u201d<\/p>\n

Additional Information<\/strong>
\nFor more on ³Ô¹Ï±¬ÁÏ Vault Quality Suite, visit: veeva.com\/QualityManufacturing<\/a>
\nConnect with ³Ô¹Ï±¬ÁÏ on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>\n<\/p>\n

About Minaris Regenerative Medicine <\/strong>
\nMinaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high-value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years of experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply life-changing therapies to patients globally. Minaris Regenerative Medicine is part of the Resonac Group. <\/p>\n

For more information, please visit www.rm.minaris.com<\/a>.<\/p>\n

About ³Ô¹Ï±¬ÁÏ Systems<\/strong>
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2023, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n

\n###\n<\/p>\n

\nContact:<\/strong>
\nJeremy Whittaker
\n³Ô¹Ï±¬ÁÏ Systems
\n+49-695-095-5486
\njeremy.whittaker@veeva.com<\/a>\n<\/p>\n

\nDeivis Mercado
\n³Ô¹Ï±¬ÁÏ Systems
\n925-226-8821
\ndeivis.mercado@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Global CDMO unifies quality content and training for greater visibility and agility.<\/p>\n","protected":false},"featured_media":70994,"parent":0,"template":"","class_list":["post-70941","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-html-content-yes","resource-area-20-quality","resource-product-20-qualitydocs","resource-product-20-training","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/70941"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/70941\/revisions"}],"predecessor-version":[{"id":70997,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/70941\/revisions\/70997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/70994"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=70941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}